Avenue Therapeutics Q3 2024 net loss $3.1M; cash $2.6M; AJ201 data expected year-end

AVENUE THERAPEUTICS, INC.

Net loss of $3.1M ($1.92/share) vs net income of $0.5M in Q3 2023.
Cash and equivalents $2.6M at Sep 30, 2024, down $2.3M from Q2 2024.
R&D expenses $2.3M, up from $0.9M in prior year; G&A $0.8M down from $1.2M.
Topline data from AJ201 Phase 1b/2a trial in SBMA expected around year-end 2024.
IV Tramadol Phase 3 safety protocol finalized with FDA; study start subject to financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.